Cargando…

Erratum. Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care 2019;42:2228–2236

Detalles Bibliográficos
Autores principales:	Sims, Emily K., Geyer, Susan, Johnson, Suzanne Bennett, Libman, Ingrid, Jacobsen, Laura M., Boulware, David, Rafkin, Lisa E., Matheson, Della, Atkinson, Mark A., Rodriguez, Henry, Spall, Maria, Larsson, Helena Elding, Wherrett, Diane K., Greenbaum, Carla J., Krischer, Jeffrey, DiMeglio, Linda A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2020
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301159/ https://www.ncbi.nlm.nih.gov/pubmed/32132004 http://dx.doi.org/10.2337/dc20-er04

Ejemplares similares

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History
por: Sosenko, Jay M., et al.
Publicado: (2015)

Understanding and preventing type 1 diabetes through the unique working model of TrialNet
por: Battaglia, Manuela, et al.
Publicado: (2017)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258–264
por: Sims, Emily K., et al.
Publicado: (2019)

Erratum. Genetics coming of age in type 1 diabetes. Diabetes Care 2019;42:189–191
por: Cerosaletti, Karen, et al.
Publicado: (2019)

Development of Autoantibodies in the TrialNet Natural History Study
por: Vehik, Kendra, et al.
Publicado: (2011)

Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials
por: Kinney, Mara, et al.
Publicado: (2023)

Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA(1c), and Insulin Dose
por: Hao, Wei, et al.
Publicado: (2016)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2008)

Alquezar-Artieda N, Kuzilkova D, Roberts J, et al. Restored biosynthetic pathways induced by MSCs serve as rescue mechanism in leukemia cells after L-asparaginase therapy. Blood Adv. 2023;7(10):2228-2236.
Publicado: (2023)

Evaluating the effect of prebiotics on the gut microbiome profile and β cell function in youth with newly diagnosed type 1 diabetes: protocol of a pilot randomized controlled trial
por: Ismail, Heba M., et al.
Publicado: (2023)

Cause or effect? A review of clinical data demonstrating beta cell dysfunction prior to the clinical onset of type 1 diabetes
por: Sims, Emily K., et al.
Publicado: (2019)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073
por: Greenbaum, Carla J., et al.
Publicado: (2013)

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

2228 The association of gastrointestinal symptoms and hypertension in persons living with HIV on HAART
por: Butler, Kierra R., et al.
Publicado: (2018)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment
por: Orban, Tihamer, et al.
Publicado: (2014)

PReS-FINAL-2236: Continuous autoinflammatory syndromes: a single-center experience in Argentina
por: Russo, RA, et al.
Publicado: (2013)

2236. Stool-Derived Inflammatory Mediators Serve as Biomarkers of Severity in Clostridium difficile Infection
por: Motyka, Jonathan, et al.
Publicado: (2019)

PB2236: POPULATION BASED INCIDENCE OF ESSENTIAL THROMBOCYTHEMIA: AN ALBANIAN STUDY (2007-2021)
por: Perolla, Adela, et al.
Publicado: (2023)

2236. Evaluation Of Antibiotic Utilization For Urinary Tract Infections In Two Community Hospitals In Miami
por: Boatwright, Renata, et al.
Publicado: (2023)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

Erratum. Preoperative Circulating Succinate Levels as a Biomarker for Diabetes Remission After Bariatric Surgery. Diabetes Care 2019;42:1956–1965
por: Ceperuelo-Mallafré, Victoria, et al.
Publicado: (2019)

The Evolution of Hemoglobin A(1c) Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence
por: Redondo, Maria J., et al.
Publicado: (2021)

Erratum. Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A(1c) Testing. Diabetes Care 2019;42:576–584
por: Evron, Joshua M., et al.
Publicado: (2020)

Erratum. Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program. Diabetes Care 2019;42:1209–1216
por: Pratte, Katherine A., et al.
Publicado: (2019)

Most Youth With Type 1 Diabetes in the T1D Exchange Clinic Registry Do Not Meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes Clinical Guidelines
por: Wood, Jamie R., et al.
Publicado: (2013)

Twenty-year trends in racial and ethnic enrollment in large diabetes randomized controlled trials
por: Zhang, Jingyi, et al.
Publicado: (2022)

Defining Pathways for Development of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report
por: Wherrett, Diane K., et al.
Publicado: (2015)

2228. Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Patients with Diabetes: Outcomes from a Global Phase 3 Study of Delafloxacin (DLX)
por: Kaidashev, Igor, et al.
Publicado: (2019)

Exploring ethnic representativeness in diabetes clinical trial enrolment from 2000 to 2020: a chronological survey
por: Li, Guowei, et al.
Publicado: (2022)

Response to Comment on Laiteerapong et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care 2019;42:416–426
por: Laiteerapong, Neda, et al.
Publicado: (2019)

Age- and Gender-Specific Components of the Metabolic Syndrome in 2228 First Graders: The PEP Family Heart Study
por: Schwandt, Peter, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_uifj914h3p5emr8dtbfd09e5lg